Systematic review and statistical analysis of the integrity of 33 randomized controlled trials

Mark J. Bolland,
MBCChB, PhD
Alison Avenell, MBBS,
MD
Greg D. Gamble, MSc
Andrew Grey, MD

Correspondence to
Dr. Bolland:
m.bolland@auckland.ac.nz

ABSTRACT

Background: Statistical techniques can investigate data integrity in randomized controlled trials (RCTs). We systematically reviewed and analyzed all human RCTs undertaken by a group of researchers, about which concerns have been raised.

Methods: We compared observed distributions of p values for between-groups differences in baseline variables, for standardized sample means for continuous baseline variables, and for differences in treatment group participant numbers with the expected distributions. We assessed productivity, recruitment rates, outcome data, textual consistency, and ethical oversight.

Results: The researchers were remarkably productive, publishing 33 RCTs over 15 years involving large numbers of older patients with substantial comorbidity, recruited over very short periods. Treatment groups were improbably similar. The distribution of p values for differences in baseline characteristics differed markedly from the expected uniform distribution ($p = 5.2 \times 10^{-82}$). The distribution of standardized sample means for baseline continuous variables and the differences between participant numbers in randomized groups also differed markedly from the expected distributions ($p = 4.3 \times 10^{-4}$, $p = 1.5 \times 10^{-5}$, respectively). Outcomes were remarkably positive, with very low mortality and study withdrawals despite substantial comorbidity. There were very large reductions in hip fracture incidence, regardless of intervention (relative risk 0.22, 95% confidence interval 0.15–0.31, $p < 0.0001$, range of relative risk 0.10–0.33), that greatly exceed those reported in meta-analyses of other trials. There were multiple examples of inconsistencies between and within trials, errors in reported data, misleading text, duplicated data and text, and uncertainties about ethical oversight.

Conclusions: A systematic approach using statistical techniques to assess randomization outcomes can evaluate data integrity, in this case suggesting these RCT results may be unreliable.

Neurology® 2016;87:2391–2402

GLOSSARY

RCT = randomized controlled trial.

Investigating concerns about the integrity of data from biomedical research is difficult.¹ One approach is to use statistical techniques to compare the observed distributions of baseline variables from a group of randomized controlled trials (RCTs) for which concerns about data integrity exist, with the expected distributions that would arise if treatment allocation occurred by chance. This approach was previously used to identify a case of fraudulent data involving at least 168 RCTs.²

Meta-analysts may identify concerns about data integrity during their careful review of large numbers of publications. While undertaking systematic reviews in osteoporosis, we considered RCTs by Yoshihiro Sato et al. (“the researchers”) for inclusion. This group of authors has published a very large number of RCTs (appendix e-1, table e-1A, references A1–A33 at Neurology.org) that collectively have substantially influenced relevant systematic reviews. Dr. Sato is the first author on 79% of these trials and holds primary oversight of the majority of these publications. Questions had been raised in journal correspondence regarding some of these papers,^{3–7} and we had additional concerns about aspects of a number of papers identified

Editorial, page 2388

Supplemental data
at Neurology.org

From the Department of Medicine (M.J.B., G.D.G., A.G.), University of Auckland, New Zealand; and Health Services Research Unit (A.A.), University of Aberdeen, Foresterhill, Scotland.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

for our reviews. We wondered whether the statistical techniques previously used for comparing distributions of baseline variables² could be applied to a systematic review of RCTs from the researchers that included 3 papers published in *Neurology*[®] (A9, A17, A23, which have been retracted; for a full list of papers in this study retracted to date, see table e-1B.). In addition, we assessed some other potentially relevant aspects of the body of RCTs including the researchers' productivity and recruitment rates, outcome data, textual consistency within and between RCTs, and ethical oversight.

METHODS In November 2012, we searched MEDLINE and Embase for all RCTs with Y. Sato or Yoshihiro Sato listed as an author, published in English or Japanese. Two hundred fifty-three potentially relevant publications were identified. After excluding unrelated articles and articles by other individuals with the same name, we identified 33 RCTs in humans (table e-1A). For each report, we extracted data on study design, ethical approval, randomization, baseline characteristics, and outcomes, and identified inconsistencies in reporting of methods and results.

Halbikath et al.⁶ suggested that "baseline data indicate that the study groups are strikingly well matched" in many RCTs reported by the researchers,⁶ who responded that this occurred "not by design but by chance." Since allocation of participants in an RCT is random, comparisons between randomized groups for independent variables at baseline should produce a uniform distribution of *p* values; for example, there is an equal likelihood of a *p* value of <0.1 and >0.9, of <0.2 and >0.8, etc. Baseline variables within an RCT are not always independent and may be correlated. However, this interdependence is unlikely to translate into substantial between-group similarities where simple randomization is used. Clustering of the *p* values for differences between groups may not occur in the same direction or to the same degree in other trials. Since any differences between groups are attributable to chance, if there is consistent clustering of variables in multiple trials, the distribution of *p* values across multiple trials from a group of clustered variables should still be approximately uniform. Therefore, across a body of RCTs, clustering is unlikely to affect the distribution of *p* values markedly. We compared the observed distribution of *p* values in deciles for all baseline comparisons with the expected distribution using the χ^2 test (Excel 2007; Microsoft, Redmond, WA). We used reported *p* values from the papers, and when these were not reported, we calculated *p* values from the reported summary data (mean, SD, or percentage) using *t* tests or 1-way analysis of variance for continuous variables and χ^2 or Fisher exact test for categorical variables (OpenEpi version 2.3.1, www.OpenEpi.com).

We undertook a complementary analysis to assess the sampling distribution of continuous variables. The central limit theorem states that if a population is repeatedly sampled, the means of these samples are approximately normally distributed. The mean of the sample means ($\bar{x}$) approximates the population mean (μ) and the SD of the sample means is the standard error of the mean (which is the population SD/ $\sqrt{n}$). Any normal distribution curve can be standardized to produce a curve with mean 0 and SD 1 using the formula $(x - \mu)/SD$. A randomized group in an RCT can be considered as a random sample from the entire trial

population. We calculated the trial population mean and SD for each baseline continuous variable from the summary data presented in the trial report. We then selected the control group (or the first presented treatment group when only active treatments were compared) and standardized the sample mean $(\bar{x} - \mu)/SEM$. We tested whether the distribution of these standardized sample means differed from the expected distribution (standardized SD of 1) using an *F* test for the equality of variance (Excel 2007), in an approach similar to that used by Carlisle.²

We assembled a dataset of 13 RCTs^{8–20} conducted by the Auckland Bone and Joint Research Group (table e-2) as a matched control group of trials that were similarly sized to the RCTs of interest, conducted over a similar time frame, and also focus on the prevention or treatment of osteoporosis in older people. We compared the distributions of *p* values and standardized sample means between this control dataset and the dataset of interest. Bootstrap resampling was used to account for ignorance of the dependence structure between differences in baseline variables and single group variance structures. We randomly selected between 350 and 450 baseline *p* values (with replacement) and between 250 and 350 baseline standardized sample means (with replacement) from both datasets, performed 2-sample Kolmogorov–Smirnov tests on these values (SAS v9.4; SAS Institute Inc., Cary, NC), and repeated this 1,000 times.

In a trial with simple randomization, the proportion of participants in each group is determined by chance, and thus the numbers of participants in the randomized groups in a set of trials will be binomially distributed.^{21,22} For a 2-arm trial with 2 participants, the probability of equal number of participants in each group (i.e., one) is 50%, for 4 participants is 37.5%, for 10 participants is 25%, and for 50 participants is 11%. For block randomization, the number of participants in each trial arm is equal in each block. Thus, any differences between the size of randomized groups arise from the last block. If the block is filled, the groups will be equal in size. For a block size of 2 or 4 in a 2-arm trial, an odd number of total participants means the groups differ by one. For a block size of 4, 2 participants in the final block gives a 2/3 probability the groups are equal in size, and a 1/3 probability that they differ by 2 participants.²² When block randomization is stratified, the same principle applies for each stratum. We used the approach of Carlisle² to assess whether the distribution of differences in numbers of participants between treatment groups in the trials conducted by the researchers is consistent with the binomial distribution.

Hip fracture was the most frequently reported fracture outcome, reported for 23 trials. Using random-effects models, we pooled these outcome data from trials by the researchers and compared the results to published contemporaneous meta-analyses of trials from other investigators. Statistical heterogeneity between trial-level summary data was assessed using the Cochran *Q* statistic (*p* < 0.10) and the *I*² statistic (*I*² > 50). Analyses were performed using Comprehensive Meta-Analysis version 2 (Biostat, Englewood, NJ).

RESULTS Productivity and recruitment rates. Table 1 shows the characteristics of the 33 human RCTs (A1–A33). Of note, these 33 RCTs were published over a 15-year period and included 5,894 participants. Three (A9, A17, A23) were published in *Neurology*. Y. Sato was the first author for 26 RCTs. Another author was the first author for the remaining 7 RCTs and a coauthor for 25 RCTs, and 3 others coauthored at least 10 RCTs. The rate of

Table 1 Study design of 33 human randomized controlled trials by the researchers

Ref	Year	Patient group	Age	Sex	Intervention	Endpoint	Duration	No.	Follow-up	Recruitment period
A1	1997	Stroke	Nil	Either	ACD vs P	BMD	6 mo	84	Monthly	NS
A2	1998	Stroke	Nil	Either	Vit K vs nil	BMD	12 mo	108	2-weekly	NS
A3	1999	Stroke	Nil	Either	Ipri vs ACD vs nil	BMD	12 mo	103	2-weekly	NS
A4	1999	PD	>65	Either	ACD vs P	BMD	18 mo	86	2-weekly	NS
A5	2000	Stroke	>65	Either	Etid vs P	BMD	56 wk	98	2-weekly	January 1997–December 1998
A6	2002	PD	>65	Female	Vit K vs nil	BMD	12 mo	120	2-weekly	NS
A7	2002	Stroke	Nil	Either	B ₁₂ vs folate vs both	Homocysteine	8 wk	191	NS	April 1997–August 2000
A8	2003	PD and NMS	Nil	Either	Methylpred vs P	Recovery	10 d	40	NS	January 1995–December 1997
A9	2003	Stroke	>65	Either	Sunlight vs nil	BMD	12 mo	258	2-weekly	NS
A10	2004	Hip fracture	Nil	Female	Etid vs P	Bone metabolism	3 mo	80	NS	April 2001–June 2002
A11	2005	Osteoporosis	Nil	Female	Etid vs Alend	BMD	12 mo	50	NS	July 2002–July 2003 ^a
A12	2005	Stroke	>65	Either	B ₁₂ vs nil	Median NCS	2 y	135	NS	NS
A13	2005	Stroke	>65	Either	B ₁₂ /folate vs P	Hip fracture	2 y	628	4-weekly	April 2000–May 2001 ^b
A14	2005	Stroke	Nil	Female	Vit D vs P	Falls	2 y	96	NS	May 2002–July 2002 ^b
A15	2005	Stroke	>65	Male	Rised vs P	Hip fracture	18 mo	280	4-weekly	April 2003–May 2003 ^a
A16	2005	AD	>65	Female	Sunlight vs nil	BMD	12 mo	264	2-weekly	NS
A17	2005	Stroke	>65	Female	Rised vs P	Hip fracture	12 mo	374	4-weekly	April 2003–July 2003 ^a
A18	2005	AD	>70	Female	Rised vs P	Fracture	18 mo	500	4-weekly	March 2003–April 2003 ^a
A19	2005	AD	>70	Female	Vit K/vit D/Ca vs nil	Osteoporosis	2 y	200	4-weekly	NS
A20	2005	Osteoporosis	>55	Female	Vibration vs nil	BMD	12 mo	50	NS	October 2002 ^b
A21	2006	ALS	Nil	Either	Etid vs P	Osteoporosis	2 y	82	NS	January 1998–August 2002
A22	2006	PD	>65	Female	Alend vs P	Hip fracture	2 y	288	4-weekly	April 2002–May 2002
A23	2007	PD	>65	Male	Rised vs P	Osteoporosis	2 y	242	4-weekly	April 2003–March 2004 ^a
A24	2008	Osteoporosis	Nil	Female	Alend vs Ral	BMD	12 mo	122	NS	NS
A25	2009	Low BMD	Nil	Male	Alend vs ACD	BMD	12 mo	112	NS	January 2005–March 2007
A26	2009	Volunteers	>50	Either	Exercise vs nil	Falls	5 mo	68	3 d/wk	July 2006–March 2007
A27	2010	Stroke	Nil	Either	Etid vs P	Hip fracture	2 y	80	Weekly	May 2005–January 2007
A28	2011	Osteoporosis	Nil	Female	Alend vs Elca	Back pain	6 mo	194	1, 3, 6 mo	April 2007–March 2008
A29	2010	AD	>70	Either	Vit K vs nil	Hip fracture	12 mo	231	4-weekly	August 2007–July 2008
A30	2011	PD	Nil	Female	Rised vs P	Hip fracture	2 y	272	4-weekly	January 2007–June 2007
A31	2011	PD	>65	Either	Sunlight vs nil	Hip fracture	2 y	324	2-weekly	NS
A32	2011	Stroke	Nil	Either	Alend vs ACD	Falls	12 mo	82	NS	October 2007–December 2008
A33	2012	Osteoporosis	>50	Female	Vibration vs nil	Physical function	6 mo	52	2 d/wk	October 2009–September 2010

Abbreviations: ACD = alphacalcidol; AD = Alzheimer disease; Age = age restriction; Alend = alendronate; ALS = amyotrophic lateral sclerosis; B₁₂ = vitamin B₁₂; BMD = bone mineral density; Ca = calcium; Elca = elcatonin; Etid = etidronate; Ipri = ipriflavone; Methylpred = methylprednisolone; NCS = nerve conduction studies; NMS = neuroleptic malignant syndrome; NS = not stated; P = placebo; PD = Parkinson disease; Ral = raloxifene; Ref = reference; Rised = risedronate; Vit = vitamin.

^a 5 trials actively recruiting participants, and ^b 3 trials with active follow-up between March and July 2003.

publication of RCTs suggests a very large well-funded research network, with access to a very large catchment of patients with substantial comorbidity who, nonetheless, are willing trial participants. Considering these practical requirements, it was surprising that there was no statement regarding funding for 30 of the 33 human RCTs. Furthermore, none of the RCTs contained a statement on trial registration,

although many trials were published before this became customary.

The human RCTs represent remarkable productivity, particularly given the frailty of the participants in several of the trials. For example, in the 5 months between March 2003 and July 2003, the researchers recruited 500 ambulatory female patients older than 70 years with Alzheimer disease living in the

community in 2 months (A18), 280 male patients older than 65 years with hemiplegic stroke in 2 months (A15), and 374 female patients older than 65 years with acute hemiplegic stroke in 4 months (A17). Compounding the workload of recruiting for these 3 trials, participants were also reviewed every 4 weeks, and during this period, there was also ongoing intensive follow-up in 3 trials involving 774 participants (A13, A14, A20) and recruitment and intensive follow-up for 2 other trials involving 292 participants (A11, A23). Despite the high workload required to conduct clinical trials on such a scale, 4 of these 8 trials listed only the same 4 coauthors (A14, A15, A17, A18), and only one additional coauthor was listed for 2 of these trials (A13, A23). However, the recent *Journal of Bone and Mineral Research* retraction notice for one paper (A16) states that the coauthors of Dr. Sato “are named as such for honorary reasons and are not responsible for the content of the manuscript.”²³ Two of the 3 papers in *Neurology* reported details on potential participant eligibility. In one, <10% of potential participants were ineligible despite very restrictive inclusion criteria (A9). In both, >85% of people approached were enrolled (A9, A23).

Neuroleptic malignant syndrome can rarely occur following reduction or withdrawal of levodopa therapy. The researchers identified 40 patients with Parkinson disease with this syndrome over 3 years in a single institution, Futase Social Insurance Hospital, which has only 55 inpatient beds and 4 clinicians (<http://futase-hp.jp/about/outline.php>) (A8). A correspondent found this astonishing because clinicians at their institution, which has a special interest in Parkinson disease, could only “recall 2 such cases in living memory.”²³ Correspondents also expressed disbelief at the recruitment rate in the female stroke trial (A17) because, in their experience, <10% of stroke admissions would meet the eligibility criteria.⁴

Improbably similar randomized treatment groups. In 32 human RCTs, baseline data for all participants in all randomized groups were presented for 513 variables; data were only presented for study completers in one RCT (A1). Figure 1A shows the distribution of p values for between-groups comparisons of these 513 variables. Of note, 52% of p values were >0.8, while only 6%, 14%, and 27% of p values were <0.2, <0.4, and <0.6, respectively. This distribution is highly unlikely to have arisen by chance ($p = 5.2 \times 10^{-82}$). In the 25 RCTs with Y. Sato as the first author, the distribution of p values differed significantly from the expected distribution ($p = 3.8 \times 10^{-100}$) (figure 1C). Figure 1B shows the distribution of the standardized sample means for 402 baseline continuous variables. The SD of these

standardized sample means was 0.84, and the distribution differed markedly from the expected distribution ($p = 4.3 \times 10^{-4}$), with values clustered more tightly around the mean than expected. Figure 1D shows that in the 25 RCTs with Y. Sato as the first author, the distribution of standardized sample means differed from the expected distribution with values clustered tightly around the mean ($p = 1.5 \times 10^{-11}$).

The distribution of p values from 918 baseline variables from 13 RCTs in the control dataset was consistent with the expected independent uniform distribution ($p = 0.07$, figure e-1), and the SD of the standardized sample means from 726 baseline variables was 1.02, also consistent with the expected distribution ($p = 0.78$). However, comparison of baseline p values and standardized sample means from the RCTs of interest and the control RCTs using bootstrap resampling showed marked differences in distributions (baseline p values: $p < 0.001$ in all 1,000 comparisons; standardized sample means: median p value 6×10^{-4} , 95% confidence interval 2×10^{-7} to 0.021).

Table 2 shows that the numbers of participants in each treatment group were the same in 27 of 30 two-arm RCTs. For all 33 trials, randomization in blocks was stated specifically for 10 RCTs, using computer-generated random numbers for 13 RCTs, no details were reported for 9 RCTs, and one trial was pseudorandomized using alternate allocation. Four trials that used block randomization were stratified by site, and for one trial, participant numbers by site were reported in correspondence about the paper (A18). For another 2 trials (A13, A15), stratified randomization was not described, but multiple sites and participant numbers by site were reported in corrections or correspondence about the papers. We assumed randomization was stratified by site for these 2 trials. Figure 2 shows that the distribution of differences in participant numbers between the treatment groups differs from the expected distribution ($p = 5 \times 10^{-33}$) in 20 two-arm RCTs presumed to use simple randomization (i.e., unless block randomization was stated). For the 10 RCTs that used block randomization, the observed distribution of differences was consistent with the expected distribution ($p = 0.48$). When all 30 two-arm trials were considered, the observed distribution of differences differed from the expected distribution ($p = 1.5 \times 10^{-5}$). Finally, we treated all trials as if they used randomization with a block size of 4 unless another approach was explicitly stated (except trial A1, which has a difference of 6 participants between groups meaning that block randomization is very unlikely). The distribution of differences in participant numbers between the treatment groups still differs from the expected

Figure 1 Distribution of *p* values and standardized sample means in 32 randomized controlled trials by the researchers

(A, C, E, G) The observed vs expected distribution of *p* values by decile in 32 randomized controlled trials for all baseline variables (A), in 25 trials with Y. Sato as first author (C), and as illustrative examples, for all baseline variables in study A13, Study A23. Continued

distribution. The expected number of trials with equal participants is 22/30 and with a difference of 2 participants is 5/30, whereas the observed number of trials was 27 and 0, respectively ($p = 0.04$).

The results of these separate but complementary analyses strongly suggest there has been a systematic failure of randomization in these trials because the randomized groups are much more similar than would be expected by chance, if randomization had occurred successfully.

Remarkably positive outcomes. The outcomes reported by the researchers are generally extremely positive and inconsistent with contemporaneous literature. Despite studying frail elderly individuals with substantial comorbidity, table 2 shows that participant withdrawals from the trials were few in number and very well matched between treatment groups. In fact, only 519 participants (8.8%) did not complete the trials, which is surprising because participants had very high rates of hip fracture (table 2) and substantial background comorbidity, both of which are associated with high mortality.

Figure 3 shows the observed reductions in hip fracture in RCTs with a control group that received either placebo or no treatment for the various treatments studied by the researchers. There were consistent and substantial reductions in hip fracture incidence regardless of the treatment studied (relative risk 0.22, 95% confidence interval 0.15–0.31, $p < 0.0001$, range of relative risk 0.10–0.33) with very little statistical heterogeneity between the results. This lack of heterogeneity is very surprising given the relatively large numbers of agents and the diversity of the populations studied. Furthermore, figure 3 also shows that the magnitude of these reductions is substantially greater than those observed in meta-analyses of other trials for these agents,^{24–26} and the confidence intervals around the pooled result for the researchers' trials do not overlap the confidence intervals around the pooled results for trials conducted by other investigators. Thus, the very positive results of the trials by the researchers are inconsistent with results from other groups.

Logical and other inconsistencies. There are a number of inconsistent results *between* trials conducted by the researchers. For example, in a trial in Alzheimer disease (A29), the control group received risedronate

and calcium and had a hip fracture rate of 86/1,000 patient-years. Yet, the active treatment arm of another trial in patients with Alzheimer disease (A18) who received risedronate, calcium, and vitamin D had a hip fracture rate of 15/1,000 patient-years. Similarly, trials in Parkinson disease in which the control group received placebo plus vitamin D reported very high rates of hip fracture (49, 37, and 55/1,000 patient-years) (A22, A23, A30) but when sunlight exposure was used as the active treatment arm to improve vitamin D status, the hip fracture rate was only 9/1,000 patient-years (A31). Likewise, when vitamin D was used in the placebo arm of trials, bone density decreased substantially by 0.9% to 3.2% (A18, A22, A23, A30), whereas when sunlight exposure was studied as active treatment, bone mineral density increased by 2.7% to 3.8% (A16, A31).

There are also inconsistencies *within* trials. For example, in one *Neurology* paper (A9), the authors state that 109 participants were randomized to one group and 108 to the other. However, the participant flow diagram shows 129 participants in each group with 109 and 108, respectively, completing the trial. In one study (A22) it is stated that randomization was performed by one of the authors "(J.I.)," and in the same paragraph, it is stated that "follow-up assessment of patient's condition was performed by physicians (Y.S., J.I.) who did not participate in the initial randomization." In one study (A29), it is stated that randomization was stratified by site, yet only one site was mentioned in the methods section. In another study (A15), participants were eligible for inclusion if they had sustained a stroke at least 3 months before the study began, but the mean duration of illness at baseline in both randomized groups was 90 days, or slightly less than 3 months, which appears implausible.

There are also errors in the reported outcome data. In 14 RCTs, rates of hip fracture per 1,000 patient-years are reported (table 2). For 11 of these trials, the reported rates can simply be calculated with the equation: rate = number with hip fracture/(participants $\times$ duration of trial). These rates are not correct because they do not account for loss to follow-up or censoring of participants who have sustained a hip fracture. Data on adverse events are also misreported. For example, in 2 of the 3

Figure 1 legend, continued:

the subject of the recent expression of concern from the *Journal of the American Medical Association*²⁷ (E), and study A23, published in *Neurology* (G). The dotted line shows the expected proportion (0.1) for each decile. (B, D, F, H) The observed vs expected distribution of standardized sample means for all continuous baseline variables in these 32 trials (B) and in 25 trials with Y. Sato as first author (D), and for all continuous baseline variables in study A13 (F) and study A23 (H). The expected distribution is a normal distribution curve with mean 0 and SD 1 (dotted line). The solid line is a normal curve of best fit to the observed data. All the graphs show that the observed distribution differs markedly from the expected distribution.

Table 2 Participant numbers, randomization methods, hip fractures, and withdrawals in 33 randomized controlled trials by the researchers

Study	Participants		Hip fracture				Withdrawals	
	Control/treat	Method of randomization	No.		Rate (per 1,000 patient-y)		No.	
			Control	Treat	Control	Treat	Control	Treat
A1	39/45	Not described	4	0			5	15
A2	54/54	Not described	1	0			6	3
A3	34/34/35	Not described	1	0/0			4	3/2
A4	43/43	CG random no.	6	1			3	3
A5	49/49	CG random no.	2	0			2	3
A6	60/60	CG random no.	8	1			4	6
A7	63/64/64 ^a	CG random no.	NA		NA		NA	0/0/0
A8	20/20	CG random no.					0	0
A9	129/129	CG random no.	6	1	56	9	21	20
A10	40/40	CG random no.					3	4
A11	25/25 ^a	Alternating	NA		NA		NA	0/0
A12	68/67	CG random no.					5	6
A13	314/314	CG random no., permuted blocks of 4	27	6	43	10	36	33
A14	48/48	CG random no., permuted blocks of 4	4	0	44	0	6	5
A15	140/140	CG random no., permuted blocks of 4	10	2	51	10	7	6
A16	132/132	CG random no.	9	2	74	16	11	10
A17	187/187	CG random no.	7	1	40	5	14	15
A18	250/250	CG random no., strat. permuted blocks of 4	19	5	57	15	20	19
A19	100/100	CG random no.	15	2	85	11	12	10
A20	25/25	Not described	0	0			0	0
A21	41/41	CG random no., strat. permuted blocks of 2					3	4
A22	144/144	CG random no., permuted blocks of 4	14	4	49	14	15	13
A23	121/121	CG random no., permuted blocks of 4	9	3	37	12	9	10
A24	61/61 ^a	Not described	NA		NA		NA	9/11
A25	56/56 ^a	Not described						14/11
A26	34/34	Not described					0	1
A27	40/40	CG random no., strat. permuted blocks of 2	2	0	56	0	4	3
A28	97/97 ^a	Not described	NA	0/0	NA		NA	1/0
A29	115/116	CG random no., strat. permuted blocks of 4	10	2	86	17	27	23
A30	136/136	CG random no., permuted blocks of 4	15	3	55	11	12	10
A31	162/162	CG random no.	11	3	34	9	8	6
A32	41/41 ^a	CG random no.	NA	1/0	NA		NA	1/2
A33	26/26	Not described					0	0

Abbreviations: CG = computer generated; NA = not applicable as there was no control group; strat. = stratified by site. Blanks indicate data not reported by the researchers.

^aIndicates active treatment comparison studies.

Figure 2 Distribution of differences in participant numbers between randomized groups

The observed and expected distribution of participant numbers between randomized groups in 30 two-arm randomized controlled trials by the researchers. Trial A11, which was pseudorandomized, is excluded from these analyses. (A) The results from 20 trials presumed to use simple randomization, and (B) the results from 10 trials that used block randomization.

Neurology papers, it was stated that no adverse events (A17) or no serious adverse events (A23) occurred during the trial. However in A17, 10 participants withdrew because of death or intercurrent illness, 87 experienced at least one fall, and 8 had a hip fracture. Likewise, in A23, 7 participants withdrew because of death or intercurrent illness, 12 had a hip fracture, and there was an average of 1.5 falls per participant during the trial.

Misleading text. In one study (A13), the researchers claimed to have recruited 628 trial participants from a single site. In a later correction, they stated that there were 3 additional unnamed hospitals and that the originally stated site actually recruited only 53 of 628 participants, the smallest number by some degree. Similarly, in 2 studies (A15, A18), the researchers claimed to have recruited 280 male patients

with stroke and 500 patients with Alzheimer disease, respectively, from a single site. In a later correction, they stated that there were 2 additional unnamed hospitals. The researchers stated that the reason for this misinformation was that “these hospitals were reluctant to have their names in the article.” Given the large size and intensive nature of these trials, and the absence of statements regarding funding, we presume the trials were effectively funded by the hospitals involved, with substantial trial input from other unnamed hospital staff. It is hard to understand why the hospital and its staff would not accept any recognition of their substantial contributions.

Duplicate data and text. There are examples of strikingly similar text in the reports, including duplicate outcome data. Table 3 shows that the reported mean and SD for fall rates were identical in 3 studies (A4, A6, A9) for both the treatment and control groups, and another study (A19) had identical SD to the earlier studies but the mean differed by 1 unit for both the treatment and control groups. Later, these data were altered without explanation in corrections for 2 of these trials (A6, A9). Duplicated text is also apparent when logical errors arise. Table 3 shows an example of 2 studies with identical exclusion criteria, but one criterion does not make sense for one trial because it only applies to women, but only men were eligible to participate in the trial. Some examples of duplicated text are extensive. The majority of the text in one article (A16) is identical or nearly identical to that of a later article (A31) (table e-3).

Ethical oversight. In the 33 RCTs, the ethics committee that approved the research was usually listed as the institutional or local ethics committee (22 studies). By using all the published information regarding the ethics committee approval and the location of the study, it appears that ethical approval was granted by the ethics committee of Futase Social Insurance Hospital in 11 RCTs, Mitate Hospital for 10 RCTs, Keiyu Orthopaedic Hospital for 5 RCTs, multiple hospital committees in 2 RCTs, and in 5 RCTs, the committee could not be identified. We searched the internet for “ethics” and “Mitate Hospital” or “Futase” and were unable to identify any studies performed by other groups approved by either of these ethics committees. With only 4 clinicians practicing at Futase Hospital, it seems likely that members of the Futase Hospital ethics committee had at least some clinical relationships with at least some of the coauthors of the papers by the researchers. In fact, in at least 6 studies (A9, A16, A17, A21, A27, A31), the chairperson of the ethics committee appeared to be involved with the

Figure 3 Relative risk of hip fracture in randomized controlled trials by the researchers

Meta-analysis showing a 78% reduction in relative risk ($p < 0.0001$) of hip fracture in 19 randomized controlled trials by the researchers with a control group that received either a placebo or no treatment. For comparison, the results for agents in meta-analyses of other trials are shown.²⁴⁻²⁶ There are insufficient data for hip fracture outcomes from trials of alphacalcidol,²⁶ B₁₂/folate, or vitamin K by other investigators, but vitamin K is reported to have no effect on bone density²⁹ or vertebral fracture risk.³⁰ There was a statistically significant ($p < 0.05$) interaction between the risk of hip fracture in the researchers' trials and the risk of hip fracture for each of the agents in trials by other investigators.

conduct of the study as this person is reported to have performed the randomization and allocation of participants to treatment groups.

DISCUSSION Our systematic review and application of established methods to examine data integrity to

the 33 human RCTs published by the researchers raises serious concerns about the integrity and validity of the reported results. Objective evidence for these concerns is provided by the statistical analyses, which demonstrate a systematic failure of randomization, and the consistently outlying outcome data when

Table 3 Examples of duplication of text in articles by the researchers

Article	Text	Article	Comparative text	Comment
A4	Falls rate (mean, SD): treatment group 1.3 (1.9), control group 1.4 (1.8)	A6, A9	Treatment group 1.3 (1.9), control group 1.4 (1.8)	
		A19	Treatment group 2.3 (1.9), control group 2.4 (1.8)	
A22	Patients with impairment of renal, hepatic, cardiac, or thyroid function or those who had known causes of osteoporosis, such as primary hyperparathyroidism or renal osteodystrophy, were excluded from this study. Patients were excluded if they had been treated with corticosteroids, estrogens, calcitonin, bisphosphonate, calcium, or vitamins D and K for 3 months or more during the 12 mo preceding the study; and those who had been administered these agents for even a brief period during the preceding 2 mo were also excluded.	A23	Patients with impairment of renal, hepatic, cardiac, or thyroid function or those who had known causes of osteoporosis, such as primary hyperparathyroidism or renal osteodystrophy, were excluded from this study. Patients were excluded if they had been treated with corticosteroids, estrogens, calcitonin, bisphosphonate, calcium, or vitamins D and K for 3 mo or more during the 12 mo preceding the study; and those who had been administered these agents for even a brief period during the preceding 2 mo were also excluded.	Trial A23 was restricted to men. The exclusion criterion regarding estrogen treatment does not make sense in context of elderly males with Parkinson disease.
A16		A31		The highlighted text in A16 is identical or nearly identical to the text in A31 (table e-3, included with permission from Wiley).

compared to those from other researchers. Taken together with the implausible productivity of the group, internal inconsistencies for outcome data in their work, duplication of data, numerous misleading statements and errors, and concerns regarding ethical oversight, our analysis suggests that the results of at least some of these trials are not reliable. Recently, the *Journal of the American Medical Association* has issued an expression of concern about one trial (A13), and the *Journal of Bone and Mineral Research* an expression of concern followed by retraction of another trial (A16), both precipitated by our concerns.^{23,27,28}

Two issues arise from our analyses of distribution of *p* values and standardized sample means for considering the success or failure of randomization. There will be differences in *p* values and standardized sample means calculated from published summary data compared to values calculated from raw data because of rounding of variables. However, any differences would be small and could not explain the marked departure from the expected distributions that we found. A second issue is that some of the baseline variables may not be independent. For example, if by chance, one randomized group is older than the other, this group may have similar differences in variables correlated with age, such as bone mineral density. This could lead to clustering of *p* values and standardized means within an individual RCT. However, clustering may not occur in the same direction or magnitude in other trials. Since any differences between groups are attributed to chance, consistent clustering of variables should still produce an approximately uniform distribution of *p* values of between-groups comparisons from a group of clustered baseline variables across multiple trials. Therefore, clustering of results from individual RCTs is unlikely to affect the analysis of

a body of RCTs markedly. However, results from individual RCTs or small differences from expected variations for a body of RCTs should be interpreted cautiously.

Previously, Carlisle analyzed the distribution of standardized sample means from 168 RCTs published by an individual author, the integrity of whose work had been questioned, along with data from 366 RCTs from other authors.² He reported that the observed distribution of standardized sample means for weight, height, and age from the 366 control RCTs were consistent with expected (range of standardized SD 0.93–1.06), whereas the distributions of sample means from the 168 RCTs of interest were not (range SD 0.55–0.62). Similarly, pooling all continuous variables produced a distribution similar to expected for the 366 RCTs from other authors, whereas the distribution was markedly different to expected for the variables from the 168 RCTs of interest.² The results of our analyses of the data from the researchers were similar to the results of Carlisle's analysis, with observed distributions of sample means markedly different to expected. A limitation of this work, and the previous work by Carlisle, is that the statistical theory underpinning the methods used has not been fully developed.

In summary, statistical techniques, such as those used in this report and similar approaches used previously by Carlisle,² that involve comparisons of the observed distributions of baseline *p* values or baseline variables in RCTs with the expected distributions may be useful when considering or investigating the integrity of a group of RCTs.

AUTHOR CONTRIBUTIONS

Mark Bolland: drafting/revising manuscript, study concept or design, analysis or interpretation of data, acquisition of data, statistical analysis. Alison Avenell: drafting/revising manuscript, study concept or design, analysis or interpretation of data. Greg Gamble: drafting/revising manuscript, study concept or design, analysis or interpretation of data,

statistical analysis. Andrew Grey: drafting/revising manuscript, study concept or design, analysis or interpretation of data. Dr. Bolland has full responsibility for the data, the analyses and interpretation, and the conduct of the research, has full access to all of the data, and has the right to publish any and all data, separate and apart from the guidance of any sponsor.

ACKNOWLEDGMENT

The authors are grateful to Bill Gillespie (Hull York Medical School, UK), Lesley Gillespie (University of Otago, New Zealand), and David Torgerson (University of York, UK) for earlier discussions regarding these trials. The authors are also grateful for the assistance of Fiona Stewart (Information Specialist) and Mari Imamura (Research Fellow and native Japanese speaker) from the University of Aberdeen. The authors thank Doug Altman and anonymous referees for their comments on previous drafts of this report.

STUDY FUNDING

Funded by the Health Research Council of New Zealand. The Health Services Research Unit is core funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorate. Role of the funding source: the sponsors of the study had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

DISCLOSURE

The authors report no disclosures relevant to the manuscript. Go to [Neurology.org](#) for full disclosures.

Received December 4, 2015. Accepted in final form August 24, 2016.

REFERENCES

- Yentis SM. Lies, damn lies, and statistics. *Anaesthesia* 2012;67:455–456.
- Carlisle JB. The analysis of 168 randomised controlled trials to test data integrity. *Anaesthesia* 2012;67:521–537.
- Clarke CE. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2004;75:510–511; author reply 511.
- Poole KE, Warburton EA, Reeve J. Risedronate therapy for prevention of hip fracture after stroke in elderly women. *Neurology* 2005;65:1513–1514; author reply 1513–1514.
- Caffrey N, Casey M, Walsh B. Substandard studies or substandard “standard-of-care.” *J Bone Miner Res* 2006;21:491; author reply 492.
- Halbckath JM, Schenk S, von Maxen A, Meyer G, Muhlhauser I. Risedronate for the prevention of hip fractures: concern about validity of trials. *Arch Intern Med* 2007;167:513–514; author reply 514–515.
- Gotzsche PC, Hrobjartsson A, Maric K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. *JAMA* 2007;298:430–437.
- Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation on bone loss in postmenopausal women. *N Engl J Med* 1993;328:460–464.
- Reid IR, Ames RW, Orr-Walker BJ, et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. *Am J Med* 2000;109:362–370.
- Reid IR, Lucas J, Wattie D, et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. *J Clin Endocrinol Metab* 2005;90:5212–5216.
- Reid IR, Mason B, Horne A, et al. Randomized controlled trial of calcium in healthy older women. *Am J Med* 2006;119:777–785.
- Bolland MJ, Grey AB, Horne AM, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. *J Clin Endocrinol Metab* 2007;92:1283–1288.
- Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. *J Clin Endocrinol Metab* 2007;92:1305–1310.
- Reid IR, Cundy T, Grey AB, et al. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial. *J Clin Endocrinol Metab* 2007;92:2446–2452.
- Reid IR, Ames R, Mason B, et al. Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. *Arch Intern Med* 2008;168:2276–2282.
- Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. *J Clin Endocrinol Metab* 2009;94:538–544.
- Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. *J Clin Endocrinol Metab* 2012;97:286–292.
- Bolland MJ, Wilsher ML, Grey A, et al. Randomised controlled trial of vitamin D supplementation in sarcoidosis. *BMJ Open* 2013;3:e003562.
- Grey A, Garg S, Dray M, et al. Low-dose fluoride in postmenopausal women: a randomized controlled trial. *J Clin Endocrinol Metab* 2013;98:2301–2307.
- Grey A, Bolland M, Fenwick S, et al. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. *Eur J Endocrinol* 2014;170:257–264.
- Altman DG, Dore CJ. Randomisation and baseline comparisons in clinical trials. *Lancet* 1990;335:149–153.
- Altman DG, Bland JM. How to randomise. *BMJ* 1999;319:703–704.
- Sato Y, Iwamoto J, Kanoko T, Satoh K. Retraction: “amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized elderly women with Alzheimer's disease: a randomized controlled trial.” *J Bone Miner Res* 2015;30:2328.
- Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. *Health Technol Assess* 2005;9:1–160.
- Wells GA, Cranney A, Peterson J, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev* 2008:CD003376.
- Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. *Cochrane Database Syst Rev* 2009:CD000227.
- Bauchner H, Fontanarosa PB. Expression of Concern: Sato et al. Effect of folate and mecobalamin on hip

- fractures in patients with stroke: a randomized controlled trial. *JAMA*. 2005;293(9):1082–1088. *JAMA* 2015;313:1914.
28. Sato Y, Iwamoto J, Kanoko T, Satoh K. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized elderly women with Alzheimer's disease: a randomized controlled trial. *J Bone Miner Res* 2015;30:1745.
29. Booth SL, Dallal G, Shea MK, Gundberg C, Peterson JW, Dawson-Hughes B. Effect of vitamin K supplementation on bone loss in elderly men and women. *J Clin Endocrinol Metab* 2008;93:1217–1223.
30. Stevenson M, Lloyd-Jones M, Papaioannou D. Vitamin K to prevent fractures in older women: systematic review and economic evaluation. *Health Technol Assess* 2009;13:iii–xi, 1–134.

This Week's *Neurology*® Podcast

Systematic review and statistical analysis of the integrity of 33 randomized controlled trials (see p. 2391)

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the December 6, 2016, issue of *Neurology*. In the second segment, Dr. Ted Burns talks with Dr. Mark Bolland about his paper on the systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Dr. Ted Burns interviews Dr. Neil Garrett about his *Nature Neuroscience* paper on dishonesty for our “What’s Trending” feature of the week. In the next part of the podcast,

Dr. Ted Burns interviews Dr. Carlos Pardo about a *Neurology Today*® story on Zika virus and Guillain-Barré syndrome detected in Colombia.

Disclosures can be found at Neurology.org.

At Neurology.org, click on “RSS” in the Neurology Podcast box to listen to the most recent podcast and subscribe to the RSS feed.

CME Opportunity: Listen to this week's *Neurology* Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

Increasing the Value of YOUR AAN Membership

FREE MOC Benefits Starting January 1, 2015

You asked and we listened. As of January 1, 2015, your robust AAN membership package includes FREE* access to online learning programs designed specifically to help you take the necessary steps toward fulfilling your maintenance of certification (MOC) requirements as mandated by the ABPN: **NeuroPI**™, **NeuroSAE**®, **NeuroLearn**™.

Learn more at AAN.com/view/MOC

**\$0 purchase price excludes Student members and Nurse Practitioner/Physician Assistant members at the lower dues rate. Free access is limited to one course per program at a time.*

Neurology[®]

Systematic review and statistical analysis of the integrity of 33 randomized controlled trials

Mark J. Bolland, Alison Avenell, Greg D. Gamble, et al.

Neurology 2016;87;2391-2402 Published Online before print November 9, 2016

DOI 10.1212/WNL.0000000000003387

This information is current as of November 9, 2016

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2016 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/87/23/2391.full
Supplementary Material	Supplementary material can be found at: http://n.neurology.org/content/suppl/2016/11/09/WNL.0000000000003387.DC1 http://n.neurology.org/content/suppl/2016/11/09/WNL.0000000000003387.DC2 http://n.neurology.org/content/suppl/2016/12/05/WNL.0000000000003387.DC3
References	This article cites 28 articles, 3 of which you can access for free at: http://n.neurology.org/content/87/23/2391.full#ref-list-1
Citations	This article has been cited by 4 HighWire-hosted articles: http://n.neurology.org/content/87/23/2391.full##otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Ethics in Neurology/Legal issues http://n.neurology.org/cgi/collection/all_ethics_in_neurology_legal_issues Professional conduct and ethics http://n.neurology.org/cgi/collection/professional_conduct_and_ethics
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2016 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.